Jonathan Kaufman

Reaction Biology Corp. specializes in kinase and epigenetic HTS and profiling services. It offers radiolabeled biochemical assays available for multiple enzyme classes including: Kinase Assays, HMT Assays, and HDAC Assays. Its products include Methyltransferase, IDH proteins, Apoptosis, DNA Demethylation, Apoptosis and NQOs. The company was founded by Scott L. Diamond in 2001 and is headquartered in Malvern, PA.

Knopp Biosciences LLC engages in the operation of a drug discovery and development company. It offers dexpramipexole product, an orally bioavaliable small molecule in development treatment of asthma, eosinophil-associated disorders and amyotrophic lateral sclerosis (ALS) disease. The company was founded by Robert Bowser and Gregory T. Hebrank in 2004 and is headquartered in Pittsburgh, PA.

Metritrack, Inc. operates as a biotechnology company which focuses on advancing the current state of breast cancer care by removing the existing limitations of breast ultrasound. Its product, Breast Volume Navigator G-1000, is designed to precisely and instantly perform automated 3D mapping of breast tissue, regardless of deformation or patient motion; essential for diagnostic and treatment purposes in the age of multi-modality imaging and not available with other systems. The company was founded in 2014 and is headquartered in Hillside, IL.

MenoGenix, Inc. operates as a biotechnology company. It focuses on development of drugs for menopause and the menopause diseases. The company was founded by Debra M. Duke and Jonathan Kaufman in 2010 and is headquartered in Aurora, CO.

Semprus BioSciences, headquartered in Cambridge, Massachusetts, is a venture-backed biomedical company with a dual mission: to provide complication-free medical devices designed to preserve patients' long-term health and quality-of-life and to contribute to healthcare cost efficiencies. Their innovative, multi-faceted approach to durable surface modifications signifies a breakthrough in medical device technology. Their current focus is to enable the first permanently dual-functional (anti-colonization and anti-thrombogenic) vascular access catheter with a single surface modification. Founded out of the Massachusetts Institute of Technology's Langer Lab, the company has developed the next-generation biofunctional surface platform - which is focused on achieving clinical benefits that far exceed current market offerings containing silver, heparin, and antibiotic coatings. Through covalent chemical bonding of their Semprus Surfaces™, a permanent non-leaching biomaterial modification to the device surface, their technology is expected to vastly improve patient outcomes by preventing serious medical complications, such as infection, blood clots, improper healing, and cell overgrowth. They have assembled a world class product development team - scientists, industry executives and clinical experts - who specialize in reducing such complications at the confluence of the human body and implantable devices.

Knopp Neurosciences, Inc. operates as a drug discovery and development company. It focused on delivering breakthrough treatments in neurological disorders. It operates through three areas: inflammation discovery platform, mitochondrial discovery platform, and ion channel discovery platform. The company was founded by Gregory T. Hebrank in 2004 and is headquartered in Pittsburgh, PA.

Immunetrics, Inc. operates as a bio-simulation company. The company was founded by Carson Chow, Timothy R. Billiar, Gilles Clermont, Mitchell P. Fink and Yoram Vodovotz in 2001 and is headquartered in Pittsburgh, PA.